The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age

By Hirota Y.   Kaji M.   Ide S.   Goto S.   Oka T.  

Vaccine, Vol. 14, Iss. 17, 1996-12 ,pp. : 1597-1602

Elsevier

Access to resources Recommend Favorite

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

By Treanor J.   Keitel W.   Belshe R.   Campbell J.   Schiff G.   Zangwill K.   Wolff M.   Klimov A.   Levandowski R.   Lambert L.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1099-1105

Elsevier

Access to resources Recommend Favorite

Vaccine-related determinants of the interleukin-2 response to influenza vaccination in healthy young and elderly adults

By McElhaney J.E.   Meneilly G.S.   Pinkoski M.J.   Lechelt K.E.   Bleackley R.C.  

Vaccine, Vol. 13, Iss. 1, 1995-01 ,pp. : 6-10

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

By Halperin S.A.   Smith B.   Mabrouk T.   Germain M.   Trepanier P.   Hassell T.   Treanor J.   Gauthier R.   Mills E.L.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1240-1247

Elsevier

Access to resources Recommend Favorite

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

By Nichol K.L.   Mallon K.P.   Mendelman P.M.  

Vaccine, Vol. 21, Iss. 17, 2003-05 ,pp. : 2216-2226

Elsevier

Access to resources Recommend Favorite